SSG
CERE

Summit Securities Group’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Summit Securities Group’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,001
Closed -$491K – 939
2024
Q2 		$491K Buy
+12,001
New +$500K 0.09% 101

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Summit Securities Group's CERE Position: Q3 2024 in Review

Summit Securities Group sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 12,001 shares — an estimated $491K sold.

Summit Securities Group first reported a position in CERE in Q2 2024 and held it in 1 quarter. The position peaked at $491K in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Summit Securities Group reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Summit Securities Group sold 12,001 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $491K.
  • Summit Securities Group first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2024 and held it in 1 quarter.
  • Summit Securities Group's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $491K in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Summit Securities Group's 13F filing for Q3 2024, filed 7 Nov 2024.